nodes	percent_of_prediction	percent_of_DWPC	metapath
Imipramine—CYP2B6—Thiotepa—urinary bladder cancer	0.104	0.223	CbGbCtD
Imipramine—ABCB1—Mitomycin—urinary bladder cancer	0.0706	0.151	CbGbCtD
Imipramine—SLC22A2—Cisplatin—urinary bladder cancer	0.0554	0.118	CbGbCtD
Imipramine—CYP3A4—Thiotepa—urinary bladder cancer	0.032	0.0684	CbGbCtD
Imipramine—CYP2B6—Cisplatin—urinary bladder cancer	0.0288	0.0614	CbGbCtD
Imipramine—CYP2E1—Etoposide—urinary bladder cancer	0.0287	0.0612	CbGbCtD
Imipramine—ADRA1B—vas deferens—urinary bladder cancer	0.027	0.161	CbGeAlD
Imipramine—ABCB1—Gemcitabine—urinary bladder cancer	0.0203	0.0433	CbGbCtD
Imipramine—CYP1A2—Fluorouracil—urinary bladder cancer	0.0199	0.0424	CbGbCtD
Imipramine—CYP2B6—Doxorubicin—urinary bladder cancer	0.0193	0.0412	CbGbCtD
Imipramine—CYP1A2—Etoposide—urinary bladder cancer	0.0166	0.0354	CbGbCtD
Imipramine—HTR7—vas deferens—urinary bladder cancer	0.0157	0.0937	CbGeAlD
Imipramine—ABCB1—Cisplatin—urinary bladder cancer	0.0148	0.0315	CbGbCtD
Imipramine—ABCB1—Etoposide—urinary bladder cancer	0.0145	0.0309	CbGbCtD
Imipramine—CHRM3—ureter—urinary bladder cancer	0.0126	0.0753	CbGeAlD
Imipramine—ABCB1—Doxorubicin—urinary bladder cancer	0.00989	0.0211	CbGbCtD
Imipramine—ABCB1—Methotrexate—urinary bladder cancer	0.00958	0.0204	CbGbCtD
Imipramine—CYP2D6—Doxorubicin—urinary bladder cancer	0.00932	0.0199	CbGbCtD
Imipramine—CHRM3—muscle of abdomen—urinary bladder cancer	0.0091	0.0542	CbGeAlD
Imipramine—CYP3A4—Etoposide—urinary bladder cancer	0.00869	0.0185	CbGbCtD
Imipramine—CYP3A4—Doxorubicin—urinary bladder cancer	0.00592	0.0126	CbGbCtD
Imipramine—CYP2C19—urine—urinary bladder cancer	0.00382	0.0228	CbGeAlD
Imipramine—KCND3—prostate gland—urinary bladder cancer	0.00354	0.0211	CbGeAlD
Imipramine—Olopatadine—S100B—urinary bladder cancer	0.00331	0.531	CrCbGaD
Imipramine—CYP1A2—urine—urinary bladder cancer	0.00312	0.0186	CbGeAlD
Imipramine—CYP2E1—urine—urinary bladder cancer	0.0028	0.0167	CbGeAlD
Imipramine—HTR2A—urine—urinary bladder cancer	0.00244	0.0145	CbGeAlD
Imipramine—ADRA1D—prostate gland—urinary bladder cancer	0.00236	0.014	CbGeAlD
Imipramine—CYP3A4—urine—urinary bladder cancer	0.00226	0.0135	CbGeAlD
Imipramine—CYP2D6—urine—urinary bladder cancer	0.00222	0.0132	CbGeAlD
Imipramine—ORM1—prostate gland—urinary bladder cancer	0.00194	0.0116	CbGeAlD
Imipramine—CHRM5—epithelium—urinary bladder cancer	0.00194	0.0115	CbGeAlD
Imipramine—SLC22A4—prostate gland—urinary bladder cancer	0.00187	0.0111	CbGeAlD
Imipramine—CHRM2—prostate gland—urinary bladder cancer	0.00181	0.0108	CbGeAlD
Imipramine—ADRA1D—epithelium—urinary bladder cancer	0.00173	0.0103	CbGeAlD
Imipramine—SLC22A2—renal system—urinary bladder cancer	0.00172	0.0102	CbGeAlD
Imipramine—SLC22A3—prostate gland—urinary bladder cancer	0.0017	0.0101	CbGeAlD
Imipramine—CHRM1—prostate gland—urinary bladder cancer	0.00165	0.00982	CbGeAlD
Imipramine—ADRA1B—renal system—urinary bladder cancer	0.00164	0.00979	CbGeAlD
Imipramine—CYP2C18—vagina—urinary bladder cancer	0.00159	0.00949	CbGeAlD
Imipramine—SLC22A4—seminal vesicle—urinary bladder cancer	0.00158	0.00941	CbGeAlD
Imipramine—ADRA1D—urethra—urinary bladder cancer	0.00158	0.0094	CbGeAlD
Imipramine—CHRM3—prostate gland—urinary bladder cancer	0.00147	0.00879	CbGeAlD
Imipramine—SLC22A3—seminal vesicle—urinary bladder cancer	0.00144	0.00857	CbGeAlD
Imipramine—ADRA1A—prostate gland—urinary bladder cancer	0.00135	0.00807	CbGeAlD
Imipramine—KCNH2—prostate gland—urinary bladder cancer	0.00131	0.00779	CbGeAlD
Imipramine—ADRA1D—female reproductive system—urinary bladder cancer	0.00129	0.00767	CbGeAlD
Imipramine—Carbamazepine—UGT2B7—urinary bladder cancer	0.00128	0.205	CrCbGaD
Imipramine—SLC22A4—renal system—urinary bladder cancer	0.00127	0.00758	CbGeAlD
Imipramine—SLC22A1—renal system—urinary bladder cancer	0.00121	0.00722	CbGeAlD
Imipramine—SLC22A3—smooth muscle tissue—urinary bladder cancer	0.0012	0.00717	CbGeAlD
Imipramine—SLC22A3—renal system—urinary bladder cancer	0.00116	0.0069	CbGeAlD
Imipramine—SLC22A3—urethra—urinary bladder cancer	0.00114	0.00678	CbGeAlD
Imipramine—KCND3—lymph node—urinary bladder cancer	0.00113	0.00674	CbGeAlD
Imipramine—KCNH2—seminal vesicle—urinary bladder cancer	0.00111	0.00659	CbGeAlD
Imipramine—Benazepril—MTHFR—urinary bladder cancer	0.00108	0.174	CrCbGaD
Imipramine—ORM1—female reproductive system—urinary bladder cancer	0.00106	0.00631	CbGeAlD
Imipramine—HRH1—prostate gland—urinary bladder cancer	0.00105	0.00625	CbGeAlD
Imipramine—CHRM3—smooth muscle tissue—urinary bladder cancer	0.00104	0.00622	CbGeAlD
Imipramine—HTR7—epithelium—urinary bladder cancer	0.00103	0.00615	CbGeAlD
Imipramine—SLC22A4—female reproductive system—urinary bladder cancer	0.00102	0.00607	CbGeAlD
Imipramine—CYP2E1—prostate gland—urinary bladder cancer	0.00101	0.006	CbGeAlD
Imipramine—CHRM3—renal system—urinary bladder cancer	0.001	0.00599	CbGeAlD
Imipramine—HTR1A—renal system—urinary bladder cancer	0.001	0.00597	CbGeAlD
Imipramine—ADRA1A—epithelium—urinary bladder cancer	0.000995	0.00593	CbGeAlD
Imipramine—HTR7—smooth muscle tissue—urinary bladder cancer	0.000994	0.00592	CbGeAlD
Imipramine—CHRM3—urethra—urinary bladder cancer	0.000987	0.00588	CbGeAlD
Imipramine—HTR7—renal system—urinary bladder cancer	0.000956	0.0057	CbGeAlD
Imipramine—HTR2C—female reproductive system—urinary bladder cancer	0.000952	0.00568	CbGeAlD
Imipramine—SLC22A3—female reproductive system—urinary bladder cancer	0.000927	0.00553	CbGeAlD
Imipramine—ADRA1A—renal system—urinary bladder cancer	0.000923	0.0055	CbGeAlD
Imipramine—SLC22A4—vagina—urinary bladder cancer	0.000922	0.00549	CbGeAlD
Imipramine—SLC6A4—female reproductive system—urinary bladder cancer	0.000903	0.00538	CbGeAlD
Imipramine—CHRM1—female reproductive system—urinary bladder cancer	0.000899	0.00536	CbGeAlD
Imipramine—KCNH2—renal system—urinary bladder cancer	0.000891	0.00531	CbGeAlD
Imipramine—SLC22A1—vagina—urinary bladder cancer	0.000878	0.00523	CbGeAlD
Imipramine—KCNH2—urethra—urinary bladder cancer	0.000875	0.00522	CbGeAlD
Imipramine—CYP2E1—seminal vesicle—urinary bladder cancer	0.000852	0.00508	CbGeAlD
Imipramine—SLC22A3—vagina—urinary bladder cancer	0.000839	0.005	CbGeAlD
Imipramine—CHRM3—female reproductive system—urinary bladder cancer	0.000805	0.0048	CbGeAlD
Imipramine—SLC6A2—female reproductive system—urinary bladder cancer	0.000795	0.00474	CbGeAlD
Imipramine—HRH1—epithelium—urinary bladder cancer	0.00077	0.00459	CbGeAlD
Imipramine—HTR7—female reproductive system—urinary bladder cancer	0.000766	0.00457	CbGeAlD
Imipramine—CYP1A2—renal system—urinary bladder cancer	0.000763	0.00455	CbGeAlD
Imipramine—HRH1—smooth muscle tissue—urinary bladder cancer	0.000742	0.00442	CbGeAlD
Imipramine—CYP2B6—renal system—urinary bladder cancer	0.000731	0.00436	CbGeAlD
Imipramine—KCNH2—female reproductive system—urinary bladder cancer	0.000714	0.00425	CbGeAlD
Imipramine—HRH1—urethra—urinary bladder cancer	0.000701	0.00418	CbGeAlD
Imipramine—CYP2E1—renal system—urinary bladder cancer	0.000686	0.00409	CbGeAlD
Imipramine—CYP2C19—vagina—urinary bladder cancer	0.000676	0.00403	CbGeAlD
Imipramine—CYP2E1—urethra—urinary bladder cancer	0.000674	0.00402	CbGeAlD
Imipramine—KCNH2—vagina—urinary bladder cancer	0.000645	0.00385	CbGeAlD
Imipramine—HTR2A—epithelium—urinary bladder cancer	0.000643	0.00383	CbGeAlD
Imipramine—ORM1—lymph node—urinary bladder cancer	0.00062	0.00369	CbGeAlD
Imipramine—HTR2A—smooth muscle tissue—urinary bladder cancer	0.00062	0.00369	CbGeAlD
Imipramine—HTR2A—renal system—urinary bladder cancer	0.000596	0.00356	CbGeAlD
Imipramine—SLC22A4—lymph node—urinary bladder cancer	0.000596	0.00355	CbGeAlD
Imipramine—CYP2B6—female reproductive system—urinary bladder cancer	0.000586	0.00349	CbGeAlD
Imipramine—ABCB1—prostate gland—urinary bladder cancer	0.000573	0.00342	CbGeAlD
Imipramine—HRH1—female reproductive system—urinary bladder cancer	0.000572	0.00341	CbGeAlD
Imipramine—Clomipramine—GSTP1—urinary bladder cancer	0.000561	0.0901	CrCbGaD
Imipramine—CYP3A4—renal system—urinary bladder cancer	0.000552	0.00329	CbGeAlD
Imipramine—CYP2E1—female reproductive system—urinary bladder cancer	0.00055	0.00328	CbGeAlD
Imipramine—CYP2D6—renal system—urinary bladder cancer	0.000543	0.00324	CbGeAlD
Imipramine—SLC22A3—lymph node—urinary bladder cancer	0.000543	0.00323	CbGeAlD
Imipramine—CYP2B6—vagina—urinary bladder cancer	0.00053	0.00316	CbGeAlD
Imipramine—HRH1—vagina—urinary bladder cancer	0.000517	0.00308	CbGeAlD
Imipramine—ABCB1—seminal vesicle—urinary bladder cancer	0.000485	0.00289	CbGeAlD
Imipramine—HTR2A—female reproductive system—urinary bladder cancer	0.000478	0.00285	CbGeAlD
Imipramine—SLC6A2—lymph node—urinary bladder cancer	0.000465	0.00277	CbGeAlD
Imipramine—CYP3A4—female reproductive system—urinary bladder cancer	0.000442	0.00264	CbGeAlD
Imipramine—CYP2D6—female reproductive system—urinary bladder cancer	0.000435	0.00259	CbGeAlD
Imipramine—HTR2A—vagina—urinary bladder cancer	0.000432	0.00258	CbGeAlD
Imipramine—ABCB1—epithelium—urinary bladder cancer	0.000421	0.00251	CbGeAlD
Imipramine—KCNH2—lymph node—urinary bladder cancer	0.000417	0.00249	CbGeAlD
Imipramine—ABCB1—renal system—urinary bladder cancer	0.000391	0.00233	CbGeAlD
Imipramine—ABCB1—urethra—urinary bladder cancer	0.000384	0.00229	CbGeAlD
Imipramine—HRH1—lymph node—urinary bladder cancer	0.000335	0.00199	CbGeAlD
Imipramine—ABCB1—female reproductive system—urinary bladder cancer	0.000313	0.00187	CbGeAlD
Imipramine—ABCB1—vagina—urinary bladder cancer	0.000283	0.00169	CbGeAlD
Imipramine—Weight decreased—Epirubicin—urinary bladder cancer	0.000256	0.00108	CcSEcCtD
Imipramine—Somnolence—Etoposide—urinary bladder cancer	0.000255	0.00108	CcSEcCtD
Imipramine—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000255	0.00108	CcSEcCtD
Imipramine—Vomiting—Thiotepa—urinary bladder cancer	0.000254	0.00107	CcSEcCtD
Imipramine—Infestation—Epirubicin—urinary bladder cancer	0.000252	0.00107	CcSEcCtD
Imipramine—Infestation NOS—Epirubicin—urinary bladder cancer	0.000252	0.00107	CcSEcCtD
Imipramine—Drowsiness—Epirubicin—urinary bladder cancer	0.000252	0.00107	CcSEcCtD
Imipramine—Rash—Thiotepa—urinary bladder cancer	0.000252	0.00107	CcSEcCtD
Imipramine—Dermatitis—Thiotepa—urinary bladder cancer	0.000251	0.00106	CcSEcCtD
Imipramine—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000251	0.00106	CcSEcCtD
Imipramine—Headache—Thiotepa—urinary bladder cancer	0.00025	0.00106	CcSEcCtD
Imipramine—Decreased appetite—Etoposide—urinary bladder cancer	0.000249	0.00106	CcSEcCtD
Imipramine—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000248	0.00105	CcSEcCtD
Imipramine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000247	0.00105	CcSEcCtD
Imipramine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000247	0.00105	CcSEcCtD
Imipramine—Fatigue—Etoposide—urinary bladder cancer	0.000247	0.00105	CcSEcCtD
Imipramine—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000247	0.00105	CcSEcCtD
Imipramine—Stomatitis—Epirubicin—urinary bladder cancer	0.000246	0.00104	CcSEcCtD
Imipramine—Jaundice—Epirubicin—urinary bladder cancer	0.000246	0.00104	CcSEcCtD
Imipramine—Constipation—Etoposide—urinary bladder cancer	0.000245	0.00104	CcSEcCtD
Imipramine—Hepatitis—Methotrexate—urinary bladder cancer	0.000242	0.00102	CcSEcCtD
Imipramine—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000242	0.00102	CcSEcCtD
Imipramine—Asthenia—Gemcitabine—urinary bladder cancer	0.000241	0.00102	CcSEcCtD
Imipramine—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000239	0.00101	CcSEcCtD
Imipramine—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000239	0.00101	CcSEcCtD
Imipramine—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000238	0.00101	CcSEcCtD
Imipramine—Weight increased—Doxorubicin—urinary bladder cancer	0.000238	0.00101	CcSEcCtD
Imipramine—Pruritus—Gemcitabine—urinary bladder cancer	0.000238	0.00101	CcSEcCtD
Imipramine—Nausea—Thiotepa—urinary bladder cancer	0.000237	0.001	CcSEcCtD
Imipramine—Urethral disorder—Methotrexate—urinary bladder cancer	0.000237	0.001	CcSEcCtD
Imipramine—Weight decreased—Doxorubicin—urinary bladder cancer	0.000237	0.001	CcSEcCtD
Imipramine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000236	0.001	CcSEcCtD
Imipramine—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000235	0.000996	CcSEcCtD
Imipramine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000234	0.000993	CcSEcCtD
Imipramine—Pruritus—Fluorouracil—urinary bladder cancer	0.000234	0.000989	CcSEcCtD
Imipramine—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000233	0.000987	CcSEcCtD
Imipramine—Infestation—Doxorubicin—urinary bladder cancer	0.000233	0.000987	CcSEcCtD
Imipramine—Drowsiness—Doxorubicin—urinary bladder cancer	0.000233	0.000987	CcSEcCtD
Imipramine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00023	0.000973	CcSEcCtD
Imipramine—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000229	0.000968	CcSEcCtD
Imipramine—Urticaria—Etoposide—urinary bladder cancer	0.000228	0.000964	CcSEcCtD
Imipramine—Stomatitis—Doxorubicin—urinary bladder cancer	0.000227	0.000962	CcSEcCtD
Imipramine—Jaundice—Doxorubicin—urinary bladder cancer	0.000227	0.000962	CcSEcCtD
Imipramine—Abdominal pain—Etoposide—urinary bladder cancer	0.000227	0.00096	CcSEcCtD
Imipramine—Body temperature increased—Etoposide—urinary bladder cancer	0.000227	0.00096	CcSEcCtD
Imipramine—Hepatitis—Epirubicin—urinary bladder cancer	0.000226	0.000958	CcSEcCtD
Imipramine—Eye disorder—Methotrexate—urinary bladder cancer	0.000226	0.000956	CcSEcCtD
Imipramine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000226	0.000956	CcSEcCtD
Imipramine—Tinnitus—Methotrexate—urinary bladder cancer	0.000225	0.000954	CcSEcCtD
Imipramine—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000225	0.000953	CcSEcCtD
Imipramine—Asthenia—Cisplatin—urinary bladder cancer	0.000225	0.000951	CcSEcCtD
Imipramine—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000224	0.00095	CcSEcCtD
Imipramine—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000223	0.000946	CcSEcCtD
Imipramine—Urethral disorder—Epirubicin—urinary bladder cancer	0.000222	0.000939	CcSEcCtD
Imipramine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.00022	0.000934	CcSEcCtD
Imipramine—Angiopathy—Methotrexate—urinary bladder cancer	0.000219	0.000929	CcSEcCtD
Imipramine—Immune system disorder—Methotrexate—urinary bladder cancer	0.000218	0.000924	CcSEcCtD
Imipramine—Dizziness—Fluorouracil—urinary bladder cancer	0.000218	0.000924	CcSEcCtD
Imipramine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000218	0.000922	CcSEcCtD
Imipramine—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000218	0.000921	CcSEcCtD
Imipramine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000214	0.000907	CcSEcCtD
Imipramine—Alopecia—Methotrexate—urinary bladder cancer	0.000214	0.000904	CcSEcCtD
Imipramine—Vomiting—Gemcitabine—urinary bladder cancer	0.000213	0.000904	CcSEcCtD
Imipramine—Mental disorder—Methotrexate—urinary bladder cancer	0.000212	0.000897	CcSEcCtD
Imipramine—Rash—Gemcitabine—urinary bladder cancer	0.000212	0.000896	CcSEcCtD
Imipramine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000211	0.000896	CcSEcCtD
Imipramine—Eye disorder—Epirubicin—urinary bladder cancer	0.000211	0.000895	CcSEcCtD
Imipramine—Tinnitus—Epirubicin—urinary bladder cancer	0.000211	0.000893	CcSEcCtD
Imipramine—Malnutrition—Methotrexate—urinary bladder cancer	0.00021	0.000891	CcSEcCtD
Imipramine—Headache—Gemcitabine—urinary bladder cancer	0.00021	0.000891	CcSEcCtD
Imipramine—Flushing—Epirubicin—urinary bladder cancer	0.00021	0.000889	CcSEcCtD
Imipramine—Cardiac disorder—Epirubicin—urinary bladder cancer	0.00021	0.000889	CcSEcCtD
Imipramine—Vomiting—Fluorouracil—urinary bladder cancer	0.00021	0.000889	CcSEcCtD
Imipramine—Hepatitis—Doxorubicin—urinary bladder cancer	0.000209	0.000886	CcSEcCtD
Imipramine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000208	0.000882	CcSEcCtD
Imipramine—Rash—Fluorouracil—urinary bladder cancer	0.000208	0.000881	CcSEcCtD
Imipramine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000208	0.000881	CcSEcCtD
Imipramine—Headache—Fluorouracil—urinary bladder cancer	0.000207	0.000876	CcSEcCtD
Imipramine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000207	0.000875	CcSEcCtD
Imipramine—Dysgeusia—Methotrexate—urinary bladder cancer	0.000206	0.000872	CcSEcCtD
Imipramine—Asthenia—Etoposide—urinary bladder cancer	0.000206	0.000871	CcSEcCtD
Imipramine—Angiopathy—Epirubicin—urinary bladder cancer	0.000205	0.000869	CcSEcCtD
Imipramine—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000205	0.000869	CcSEcCtD
Imipramine—Immune system disorder—Epirubicin—urinary bladder cancer	0.000204	0.000865	CcSEcCtD
Imipramine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000204	0.000863	CcSEcCtD
Imipramine—Pruritus—Etoposide—urinary bladder cancer	0.000203	0.000859	CcSEcCtD
Imipramine—Arrhythmia—Epirubicin—urinary bladder cancer	0.000202	0.000856	CcSEcCtD
Imipramine—Alopecia—Epirubicin—urinary bladder cancer	0.0002	0.000846	CcSEcCtD
Imipramine—Nausea—Gemcitabine—urinary bladder cancer	0.000199	0.000844	CcSEcCtD
Imipramine—Vomiting—Cisplatin—urinary bladder cancer	0.000199	0.000843	CcSEcCtD
Imipramine—Vision blurred—Methotrexate—urinary bladder cancer	0.000198	0.00084	CcSEcCtD
Imipramine—Mental disorder—Epirubicin—urinary bladder cancer	0.000198	0.000839	CcSEcCtD
Imipramine—Rash—Cisplatin—urinary bladder cancer	0.000197	0.000835	CcSEcCtD
Imipramine—Dermatitis—Cisplatin—urinary bladder cancer	0.000197	0.000835	CcSEcCtD
Imipramine—Malnutrition—Epirubicin—urinary bladder cancer	0.000197	0.000834	CcSEcCtD
Imipramine—Diarrhoea—Etoposide—urinary bladder cancer	0.000196	0.000831	CcSEcCtD
Imipramine—Nausea—Fluorouracil—urinary bladder cancer	0.000196	0.00083	CcSEcCtD
Imipramine—Eye disorder—Doxorubicin—urinary bladder cancer	0.000196	0.000828	CcSEcCtD
Imipramine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000195	0.000827	CcSEcCtD
Imipramine—Tinnitus—Doxorubicin—urinary bladder cancer	0.000195	0.000826	CcSEcCtD
Imipramine—Flushing—Doxorubicin—urinary bladder cancer	0.000194	0.000822	CcSEcCtD
Imipramine—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000194	0.000822	CcSEcCtD
Imipramine—Tension—Epirubicin—urinary bladder cancer	0.000193	0.000818	CcSEcCtD
Imipramine—Dysgeusia—Epirubicin—urinary bladder cancer	0.000193	0.000817	CcSEcCtD
Imipramine—Nervousness—Epirubicin—urinary bladder cancer	0.000191	0.00081	CcSEcCtD
Imipramine—Angiopathy—Doxorubicin—urinary bladder cancer	0.00019	0.000804	CcSEcCtD
Imipramine—Malaise—Methotrexate—urinary bladder cancer	0.00019	0.000803	CcSEcCtD
Imipramine—Dizziness—Etoposide—urinary bladder cancer	0.00019	0.000803	CcSEcCtD
Imipramine—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000189	0.0008	CcSEcCtD
Imipramine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000189	0.000799	CcSEcCtD
Imipramine—Leukopenia—Methotrexate—urinary bladder cancer	0.000188	0.000798	CcSEcCtD
Imipramine—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000187	0.000792	CcSEcCtD
Imipramine—Nausea—Cisplatin—urinary bladder cancer	0.000186	0.000787	CcSEcCtD
Imipramine—Vision blurred—Epirubicin—urinary bladder cancer	0.000186	0.000786	CcSEcCtD
Imipramine—Alopecia—Doxorubicin—urinary bladder cancer	0.000185	0.000783	CcSEcCtD
Imipramine—Mental disorder—Doxorubicin—urinary bladder cancer	0.000183	0.000776	CcSEcCtD
Imipramine—ABCB1—lymph node—urinary bladder cancer	0.000183	0.00109	CbGeAlD
Imipramine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000183	0.000774	CcSEcCtD
Imipramine—Convulsion—Methotrexate—urinary bladder cancer	0.000182	0.000772	CcSEcCtD
Imipramine—Vomiting—Etoposide—urinary bladder cancer	0.000182	0.000772	CcSEcCtD
Imipramine—Malnutrition—Doxorubicin—urinary bladder cancer	0.000182	0.000771	CcSEcCtD
Imipramine—Agitation—Epirubicin—urinary bladder cancer	0.000181	0.000766	CcSEcCtD
Imipramine—Rash—Etoposide—urinary bladder cancer	0.000181	0.000765	CcSEcCtD
Imipramine—Dermatitis—Etoposide—urinary bladder cancer	0.000181	0.000765	CcSEcCtD
Imipramine—Headache—Etoposide—urinary bladder cancer	0.00018	0.00076	CcSEcCtD
Imipramine—Tension—Doxorubicin—urinary bladder cancer	0.000179	0.000757	CcSEcCtD
Imipramine—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000178	0.000755	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000178	0.000753	CcSEcCtD
Imipramine—Malaise—Epirubicin—urinary bladder cancer	0.000178	0.000752	CcSEcCtD
Imipramine—Discomfort—Methotrexate—urinary bladder cancer	0.000177	0.000749	CcSEcCtD
Imipramine—Nervousness—Doxorubicin—urinary bladder cancer	0.000177	0.000749	CcSEcCtD
Imipramine—Syncope—Epirubicin—urinary bladder cancer	0.000177	0.000748	CcSEcCtD
Imipramine—Leukopenia—Epirubicin—urinary bladder cancer	0.000176	0.000746	CcSEcCtD
Imipramine—Palpitations—Epirubicin—urinary bladder cancer	0.000174	0.000737	CcSEcCtD
Imipramine—Confusional state—Methotrexate—urinary bladder cancer	0.000173	0.000733	CcSEcCtD
Imipramine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000173	0.000733	CcSEcCtD
Imipramine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000172	0.000727	CcSEcCtD
Imipramine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000172	0.000727	CcSEcCtD
Imipramine—Convulsion—Epirubicin—urinary bladder cancer	0.000171	0.000722	CcSEcCtD
Imipramine—Infection—Methotrexate—urinary bladder cancer	0.000171	0.000722	CcSEcCtD
Imipramine—Nausea—Etoposide—urinary bladder cancer	0.00017	0.000721	CcSEcCtD
Imipramine—Hypertension—Epirubicin—urinary bladder cancer	0.00017	0.00072	CcSEcCtD
Imipramine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000169	0.000716	CcSEcCtD
Imipramine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000168	0.000713	CcSEcCtD
Imipramine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000168	0.000712	CcSEcCtD
Imipramine—Agitation—Doxorubicin—urinary bladder cancer	0.000167	0.000709	CcSEcCtD
Imipramine—Anxiety—Epirubicin—urinary bladder cancer	0.000167	0.000707	CcSEcCtD
Imipramine—Skin disorder—Methotrexate—urinary bladder cancer	0.000167	0.000706	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000166	0.000705	CcSEcCtD
Imipramine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000166	0.000703	CcSEcCtD
Imipramine—Discomfort—Epirubicin—urinary bladder cancer	0.000166	0.000701	CcSEcCtD
Imipramine—Malaise—Doxorubicin—urinary bladder cancer	0.000164	0.000696	CcSEcCtD
Imipramine—Dry mouth—Epirubicin—urinary bladder cancer	0.000164	0.000694	CcSEcCtD
Imipramine—Anorexia—Methotrexate—urinary bladder cancer	0.000164	0.000693	CcSEcCtD
Imipramine—Syncope—Doxorubicin—urinary bladder cancer	0.000163	0.000692	CcSEcCtD
Imipramine—Leukopenia—Doxorubicin—urinary bladder cancer	0.000163	0.000691	CcSEcCtD
Imipramine—Confusional state—Epirubicin—urinary bladder cancer	0.000162	0.000686	CcSEcCtD
Imipramine—Palpitations—Doxorubicin—urinary bladder cancer	0.000161	0.000682	CcSEcCtD
Imipramine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000161	0.00068	CcSEcCtD
Imipramine—Oedema—Epirubicin—urinary bladder cancer	0.000161	0.00068	CcSEcCtD
Imipramine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.00016	0.000678	CcSEcCtD
Imipramine—Infection—Epirubicin—urinary bladder cancer	0.00016	0.000676	CcSEcCtD
Imipramine—Shock—Epirubicin—urinary bladder cancer	0.000158	0.000669	CcSEcCtD
Imipramine—Convulsion—Doxorubicin—urinary bladder cancer	0.000158	0.000668	CcSEcCtD
Imipramine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000158	0.000667	CcSEcCtD
Imipramine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000157	0.000666	CcSEcCtD
Imipramine—Hypertension—Doxorubicin—urinary bladder cancer	0.000157	0.000666	CcSEcCtD
Imipramine—Tachycardia—Epirubicin—urinary bladder cancer	0.000157	0.000664	CcSEcCtD
Imipramine—Skin disorder—Epirubicin—urinary bladder cancer	0.000156	0.000661	CcSEcCtD
Imipramine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000155	0.000658	CcSEcCtD
Imipramine—Insomnia—Methotrexate—urinary bladder cancer	0.000155	0.000658	CcSEcCtD
Imipramine—Anxiety—Doxorubicin—urinary bladder cancer	0.000155	0.000655	CcSEcCtD
Imipramine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000154	0.000653	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000154	0.000652	CcSEcCtD
Imipramine—Discomfort—Doxorubicin—urinary bladder cancer	0.000153	0.000649	CcSEcCtD
Imipramine—Anorexia—Epirubicin—urinary bladder cancer	0.000153	0.000649	CcSEcCtD
Imipramine—Somnolence—Methotrexate—urinary bladder cancer	0.000153	0.000646	CcSEcCtD
Imipramine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000152	0.000642	CcSEcCtD
Imipramine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000151	0.00064	CcSEcCtD
Imipramine—Confusional state—Doxorubicin—urinary bladder cancer	0.00015	0.000635	CcSEcCtD
Imipramine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000149	0.000632	CcSEcCtD
Imipramine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000149	0.00063	CcSEcCtD
Imipramine—Oedema—Doxorubicin—urinary bladder cancer	0.000149	0.00063	CcSEcCtD
Imipramine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000148	0.000628	CcSEcCtD
Imipramine—Fatigue—Methotrexate—urinary bladder cancer	0.000148	0.000627	CcSEcCtD
Imipramine—Infection—Doxorubicin—urinary bladder cancer	0.000148	0.000626	CcSEcCtD
Imipramine—Shock—Doxorubicin—urinary bladder cancer	0.000146	0.000619	CcSEcCtD
Imipramine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000146	0.000617	CcSEcCtD
Imipramine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000146	0.000616	CcSEcCtD
Imipramine—Insomnia—Epirubicin—urinary bladder cancer	0.000145	0.000615	CcSEcCtD
Imipramine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000145	0.000615	CcSEcCtD
Imipramine—Skin disorder—Doxorubicin—urinary bladder cancer	0.000144	0.000612	CcSEcCtD
Imipramine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000144	0.000611	CcSEcCtD
Imipramine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000144	0.000609	CcSEcCtD
Imipramine—Somnolence—Epirubicin—urinary bladder cancer	0.000143	0.000605	CcSEcCtD
Imipramine—Anorexia—Doxorubicin—urinary bladder cancer	0.000142	0.0006	CcSEcCtD
Imipramine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000142	0.000599	CcSEcCtD
Imipramine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000141	0.000599	CcSEcCtD
Imipramine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.00014	0.000595	CcSEcCtD
Imipramine—Decreased appetite—Epirubicin—urinary bladder cancer	0.00014	0.000592	CcSEcCtD
Imipramine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000139	0.000587	CcSEcCtD
Imipramine—Fatigue—Epirubicin—urinary bladder cancer	0.000139	0.000587	CcSEcCtD
Imipramine—Constipation—Epirubicin—urinary bladder cancer	0.000137	0.000582	CcSEcCtD
Imipramine—Urticaria—Methotrexate—urinary bladder cancer	0.000136	0.000578	CcSEcCtD
Imipramine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000136	0.000575	CcSEcCtD
Imipramine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000136	0.000575	CcSEcCtD
Imipramine—Insomnia—Doxorubicin—urinary bladder cancer	0.000134	0.000569	CcSEcCtD
Imipramine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000134	0.000565	CcSEcCtD
Imipramine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000132	0.000561	CcSEcCtD
Imipramine—Somnolence—Doxorubicin—urinary bladder cancer	0.000132	0.00056	CcSEcCtD
Imipramine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000131	0.000556	CcSEcCtD
Imipramine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000131	0.000554	CcSEcCtD
Imipramine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000129	0.000547	CcSEcCtD
Imipramine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000128	0.000544	CcSEcCtD
Imipramine—Fatigue—Doxorubicin—urinary bladder cancer	0.000128	0.000543	CcSEcCtD
Imipramine—Urticaria—Epirubicin—urinary bladder cancer	0.000128	0.000541	CcSEcCtD
Imipramine—Constipation—Doxorubicin—urinary bladder cancer	0.000127	0.000538	CcSEcCtD
Imipramine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000127	0.000538	CcSEcCtD
Imipramine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000127	0.000538	CcSEcCtD
Imipramine—Asthenia—Methotrexate—urinary bladder cancer	0.000123	0.000522	CcSEcCtD
Imipramine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000123	0.000519	CcSEcCtD
Imipramine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000122	0.000515	CcSEcCtD
Imipramine—Pruritus—Methotrexate—urinary bladder cancer	0.000121	0.000514	CcSEcCtD
Imipramine—Urticaria—Doxorubicin—urinary bladder cancer	0.000118	0.0005	CcSEcCtD
Imipramine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000118	0.000498	CcSEcCtD
Imipramine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000118	0.000498	CcSEcCtD
Imipramine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000117	0.000498	CcSEcCtD
Imipramine—Asthenia—Epirubicin—urinary bladder cancer	0.000115	0.000488	CcSEcCtD
Imipramine—Pruritus—Epirubicin—urinary bladder cancer	0.000114	0.000481	CcSEcCtD
Imipramine—Dizziness—Methotrexate—urinary bladder cancer	0.000114	0.000481	CcSEcCtD
Imipramine—Diarrhoea—Epirubicin—urinary bladder cancer	0.00011	0.000466	CcSEcCtD
Imipramine—Vomiting—Methotrexate—urinary bladder cancer	0.000109	0.000462	CcSEcCtD
Imipramine—Rash—Methotrexate—urinary bladder cancer	0.000108	0.000458	CcSEcCtD
Imipramine—Dermatitis—Methotrexate—urinary bladder cancer	0.000108	0.000458	CcSEcCtD
Imipramine—Headache—Methotrexate—urinary bladder cancer	0.000108	0.000456	CcSEcCtD
Imipramine—Asthenia—Doxorubicin—urinary bladder cancer	0.000107	0.000452	CcSEcCtD
Imipramine—Dizziness—Epirubicin—urinary bladder cancer	0.000106	0.00045	CcSEcCtD
Imipramine—Pruritus—Doxorubicin—urinary bladder cancer	0.000105	0.000445	CcSEcCtD
Imipramine—Vomiting—Epirubicin—urinary bladder cancer	0.000102	0.000433	CcSEcCtD
Imipramine—Nausea—Methotrexate—urinary bladder cancer	0.000102	0.000432	CcSEcCtD
Imipramine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000102	0.000431	CcSEcCtD
Imipramine—Rash—Epirubicin—urinary bladder cancer	0.000101	0.000429	CcSEcCtD
Imipramine—Dermatitis—Epirubicin—urinary bladder cancer	0.000101	0.000429	CcSEcCtD
Imipramine—Headache—Epirubicin—urinary bladder cancer	0.000101	0.000426	CcSEcCtD
Imipramine—Dizziness—Doxorubicin—urinary bladder cancer	9.83e-05	0.000416	CcSEcCtD
Imipramine—Nausea—Epirubicin—urinary bladder cancer	9.55e-05	0.000404	CcSEcCtD
Imipramine—Vomiting—Doxorubicin—urinary bladder cancer	9.45e-05	0.0004	CcSEcCtD
Imipramine—Rash—Doxorubicin—urinary bladder cancer	9.37e-05	0.000397	CcSEcCtD
Imipramine—Dermatitis—Doxorubicin—urinary bladder cancer	9.37e-05	0.000397	CcSEcCtD
Imipramine—Headache—Doxorubicin—urinary bladder cancer	9.31e-05	0.000394	CcSEcCtD
Imipramine—Nausea—Doxorubicin—urinary bladder cancer	8.83e-05	0.000374	CcSEcCtD
Imipramine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.64e-06	6.29e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—EGFR—urinary bladder cancer	7.63e-06	6.29e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—EP300—urinary bladder cancer	7.63e-06	6.29e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—MMP9—urinary bladder cancer	7.57e-06	6.24e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—CDKN1A—urinary bladder cancer	7.54e-06	6.21e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	7.53e-06	6.2e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—PTEN—urinary bladder cancer	7.52e-06	6.2e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—KRAS—urinary bladder cancer	7.48e-06	6.17e-05	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—EP300—urinary bladder cancer	7.45e-06	6.14e-05	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—EP300—urinary bladder cancer	7.44e-06	6.13e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—SRC—urinary bladder cancer	7.42e-06	6.11e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—KRAS—urinary bladder cancer	7.36e-06	6.07e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—MYC—urinary bladder cancer	7.36e-06	6.07e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—MYC—urinary bladder cancer	7.35e-06	6.06e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—KRAS—urinary bladder cancer	7.35e-06	6.05e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—KRAS—urinary bladder cancer	7.32e-06	6.03e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—ERBB2—urinary bladder cancer	7.32e-06	6.03e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—KRAS—urinary bladder cancer	7.3e-06	6.02e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—RHOA—urinary bladder cancer	7.29e-06	6.01e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—CXCL8—urinary bladder cancer	7.29e-06	6.01e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.29e-06	6e-05	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—PTEN—urinary bladder cancer	7.27e-06	5.99e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	7.26e-06	5.98e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—HRAS—urinary bladder cancer	7.25e-06	5.97e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—KRAS—urinary bladder cancer	7.23e-06	5.96e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	7.22e-06	5.95e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—KRAS—urinary bladder cancer	7.21e-06	5.94e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	7.21e-06	5.94e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—EGFR—urinary bladder cancer	7.2e-06	5.93e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—EGFR—urinary bladder cancer	7.19e-06	5.93e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—RHOA—urinary bladder cancer	7.18e-06	5.91e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—EP300—urinary bladder cancer	7.18e-06	5.91e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	7.16e-06	5.9e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—RHOA—urinary bladder cancer	7.14e-06	5.88e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—RHOA—urinary bladder cancer	7.12e-06	5.86e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—RHOA—urinary bladder cancer	7.05e-06	5.81e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—RHOA—urinary bladder cancer	7.03e-06	5.79e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—TYMS—urinary bladder cancer	7e-06	5.77e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—SRC—urinary bladder cancer	6.98e-06	5.75e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—IL2—urinary bladder cancer	6.97e-06	5.74e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	6.97e-06	5.74e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—CXCL8—urinary bladder cancer	6.95e-06	5.72e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—MYC—urinary bladder cancer	6.94e-06	5.72e-05	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—EP300—urinary bladder cancer	6.94e-06	5.71e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	6.93e-06	5.71e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	6.92e-06	5.7e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	6.92e-06	5.7e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—HRAS—urinary bladder cancer	6.9e-06	5.68e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—KRAS—urinary bladder cancer	6.8e-06	5.6e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—KRAS—urinary bladder cancer	6.79e-06	5.6e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	6.79e-06	5.6e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—EGFR—urinary bladder cancer	6.79e-06	5.6e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	6.76e-06	5.57e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	6.75e-06	5.56e-05	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—PTEN—urinary bladder cancer	6.72e-06	5.53e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—MYC—urinary bladder cancer	6.65e-06	5.48e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	6.64e-06	5.47e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—IL2—urinary bladder cancer	6.64e-06	5.47e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	6.63e-06	5.46e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—GPX1—urinary bladder cancer	6.63e-06	5.46e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	6.63e-06	5.46e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—ERBB2—urinary bladder cancer	6.61e-06	5.44e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	6.6e-06	5.43e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—ERBB2—urinary bladder cancer	6.59e-06	5.43e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	6.57e-06	5.42e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	6.56e-06	5.41e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	6.56e-06	5.4e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	6.54e-06	5.39e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	6.52e-06	5.38e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—ERBB2—urinary bladder cancer	6.52e-06	5.37e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	6.51e-06	5.36e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—EGFR—urinary bladder cancer	6.5e-06	5.36e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—ERBB2—urinary bladder cancer	6.5e-06	5.36e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	6.49e-06	5.35e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—CCND1—urinary bladder cancer	6.47e-06	5.33e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—KRAS—urinary bladder cancer	6.42e-06	5.29e-05	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—EP300—urinary bladder cancer	6.41e-06	5.28e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	6.4e-06	5.28e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PPARG—urinary bladder cancer	6.37e-06	5.24e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	6.36e-06	5.24e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	6.3e-06	5.19e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	6.29e-06	5.18e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—MMP9—urinary bladder cancer	6.28e-06	5.18e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CXCL8—urinary bladder cancer	6.27e-06	5.16e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	6.26e-06	5.16e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—CDKN1A—urinary bladder cancer	6.26e-06	5.16e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	6.25e-06	5.15e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—MYC—urinary bladder cancer	6.25e-06	5.15e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CXCL8—urinary bladder cancer	6.25e-06	5.15e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	6.25e-06	5.15e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—PTEN—urinary bladder cancer	6.25e-06	5.15e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—HRAS—urinary bladder cancer	6.23e-06	5.13e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	6.22e-06	5.13e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PPARG—urinary bladder cancer	6.21e-06	5.12e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—HRAS—urinary bladder cancer	6.21e-06	5.11e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CXCL8—urinary bladder cancer	6.19e-06	5.1e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CXCL8—urinary bladder cancer	6.17e-06	5.08e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—HRAS—urinary bladder cancer	6.15e-06	5.06e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—KRAS—urinary bladder cancer	6.15e-06	5.06e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—HRAS—urinary bladder cancer	6.13e-06	5.05e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—IL2—urinary bladder cancer	6.12e-06	5.04e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	6.12e-06	5.04e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—EGFR—urinary bladder cancer	6.12e-06	5.04e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	6.11e-06	5.04e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	6.08e-06	5.01e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	6.05e-06	4.98e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—TP53—urinary bladder cancer	6.05e-06	4.98e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—TP53—urinary bladder cancer	6.04e-06	4.98e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	6.02e-06	4.96e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—IL2—urinary bladder cancer	6.01e-06	4.95e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—IL2—urinary bladder cancer	5.99e-06	4.93e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—IL2—urinary bladder cancer	5.97e-06	4.92e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—CREBBP—urinary bladder cancer	5.97e-06	4.92e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	5.97e-06	4.91e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—EP300—urinary bladder cancer	5.96e-06	4.91e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—IL2—urinary bladder cancer	5.91e-06	4.87e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—IL2—urinary bladder cancer	5.9e-06	4.86e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	5.87e-06	4.84e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	5.86e-06	4.83e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	5.85e-06	4.82e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CCND1—urinary bladder cancer	5.84e-06	4.81e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CCND1—urinary bladder cancer	5.82e-06	4.79e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	5.81e-06	4.79e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—SRC—urinary bladder cancer	5.79e-06	4.77e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	5.79e-06	4.77e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—HRAS—urinary bladder cancer	5.78e-06	4.76e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PTEN—urinary bladder cancer	5.78e-06	4.76e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—KRAS—urinary bladder cancer	5.78e-06	4.76e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—HRAS—urinary bladder cancer	5.78e-06	4.76e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	5.77e-06	4.75e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CCND1—urinary bladder cancer	5.76e-06	4.75e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	5.76e-06	4.74e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CCND1—urinary bladder cancer	5.75e-06	4.74e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—TP53—urinary bladder cancer	5.7e-06	4.7e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	5.7e-06	4.69e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	5.69e-06	4.68e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	5.68e-06	4.68e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MMP9—urinary bladder cancer	5.67e-06	4.67e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	5.67e-06	4.67e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	5.67e-06	4.67e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PTEN—urinary bladder cancer	5.66e-06	4.66e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	5.65e-06	4.66e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MMP9—urinary bladder cancer	5.65e-06	4.65e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	5.65e-06	4.65e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—PTEN—urinary bladder cancer	5.63e-06	4.64e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CDKN1A—urinary bladder cancer	5.63e-06	4.64e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	5.62e-06	4.63e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—PTEN—urinary bladder cancer	5.62e-06	4.63e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MMP9—urinary bladder cancer	5.6e-06	4.61e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MMP9—urinary bladder cancer	5.58e-06	4.6e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CDKN1A—urinary bladder cancer	5.57e-06	4.59e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—PTEN—urinary bladder cancer	5.56e-06	4.58e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CDKN1A—urinary bladder cancer	5.56e-06	4.58e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—PTEN—urinary bladder cancer	5.55e-06	4.57e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—EP300—urinary bladder cancer	5.51e-06	4.54e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—EP300—urinary bladder cancer	5.49e-06	4.52e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—TP53—urinary bladder cancer	5.46e-06	4.5e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—HRAS—urinary bladder cancer	5.45e-06	4.49e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	5.45e-06	4.49e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	5.42e-06	4.47e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	5.4e-06	4.45e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	5.4e-06	4.45e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—EP300—urinary bladder cancer	5.4e-06	4.45e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—EP300—urinary bladder cancer	5.39e-06	4.44e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—EP300—urinary bladder cancer	5.37e-06	4.43e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—EP300—urinary bladder cancer	5.36e-06	4.41e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	5.34e-06	4.4e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	5.34e-06	4.4e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—SRC—urinary bladder cancer	5.34e-06	4.4e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	5.33e-06	4.39e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—EP300—urinary bladder cancer	5.3e-06	4.37e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	5.3e-06	4.37e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—EP300—urinary bladder cancer	5.29e-06	4.36e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	5.25e-06	4.33e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—SRC—urinary bladder cancer	5.24e-06	4.32e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—SRC—urinary bladder cancer	5.23e-06	4.31e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—HRAS—urinary bladder cancer	5.22e-06	4.3e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—SRC—urinary bladder cancer	5.21e-06	4.29e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—MYC—urinary bladder cancer	5.19e-06	4.28e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—SRC—urinary bladder cancer	5.16e-06	4.25e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—SRC—urinary bladder cancer	5.14e-06	4.24e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—TP53—urinary bladder cancer	5.14e-06	4.23e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	5.11e-06	4.21e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—EGFR—urinary bladder cancer	5.08e-06	4.18e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	5.04e-06	4.15e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	5.02e-06	4.14e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	5.01e-06	4.13e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	5.01e-06	4.13e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PPARG—urinary bladder cancer	4.96e-06	4.09e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—HRAS—urinary bladder cancer	4.91e-06	4.05e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PTGS2—urinary bladder cancer	4.89e-06	4.03e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—KRAS—urinary bladder cancer	4.8e-06	3.95e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MYC—urinary bladder cancer	4.78e-06	3.94e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	4.76e-06	3.93e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	4.72e-06	3.89e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	4.71e-06	3.88e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MYC—urinary bladder cancer	4.7e-06	3.87e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MYC—urinary bladder cancer	4.68e-06	3.86e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	4.68e-06	3.86e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MYC—urinary bladder cancer	4.67e-06	3.85e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MYC—urinary bladder cancer	4.62e-06	3.81e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MYC—urinary bladder cancer	4.61e-06	3.8e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	4.61e-06	3.79e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	4.6e-06	3.79e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	4.59e-06	3.79e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—EGFR—urinary bladder cancer	4.58e-06	3.77e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—EGFR—urinary bladder cancer	4.57e-06	3.76e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—EGFR—urinary bladder cancer	4.52e-06	3.73e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—EGFR—urinary bladder cancer	4.51e-06	3.71e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	4.48e-06	3.69e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	4.45e-06	3.67e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	4.42e-06	3.64e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PTEN—urinary bladder cancer	4.37e-06	3.6e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	4.35e-06	3.58e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	4.34e-06	3.58e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—KRAS—urinary bladder cancer	4.33e-06	3.56e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—KRAS—urinary bladder cancer	4.31e-06	3.55e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	4.28e-06	3.53e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—KRAS—urinary bladder cancer	4.27e-06	3.52e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PTEN—urinary bladder cancer	4.26e-06	3.51e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—TP53—urinary bladder cancer	4.26e-06	3.51e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—KRAS—urinary bladder cancer	4.26e-06	3.51e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	4.26e-06	3.51e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—EP300—urinary bladder cancer	4.16e-06	3.43e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—HRAS—urinary bladder cancer	4.08e-06	3.36e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—EP300—urinary bladder cancer	4.06e-06	3.35e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	4.02e-06	3.31e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—TP53—urinary bladder cancer	3.93e-06	3.24e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	3.9e-06	3.21e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	3.87e-06	3.19e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—TP53—urinary bladder cancer	3.86e-06	3.18e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—TP53—urinary bladder cancer	3.85e-06	3.17e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—TP53—urinary bladder cancer	3.83e-06	3.16e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—EP300—urinary bladder cancer	3.83e-06	3.16e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	3.83e-06	3.15e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—TP53—urinary bladder cancer	3.8e-06	3.13e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—TP53—urinary bladder cancer	3.79e-06	3.12e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	3.76e-06	3.1e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	3.7e-06	3.05e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	3.69e-06	3.04e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—HRAS—urinary bladder cancer	3.68e-06	3.03e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.68e-06	3.03e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—HRAS—urinary bladder cancer	3.67e-06	3.02e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—HRAS—urinary bladder cancer	3.63e-06	2.99e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—HRAS—urinary bladder cancer	3.62e-06	2.98e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PTEN—urinary bladder cancer	3.4e-06	2.8e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—EP300—urinary bladder cancer	3.24e-06	2.67e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.01e-06	2.48e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.63e-06	2.16e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.5e-06	2.06e-05	CbGpPWpGaD
